NEW DELHI: In a major public health intervention, the Union Ministry of Health and Family Welfare has officially moved the widely prescribed drug Pregabalin from Schedule H to the much more stringent Schedule H1 of the Drugs Rules, 1945.
The mandate, finalized via Gazette Notification G.S.R. 377(E), introduces tight supply-chain tracking and retail restrictions to combat a rising wave of drug abuse and illegal trafficking across several states.
Key Takeaways
-
The Reason for the Crackdown: While Pregabalin is a critical medication medically indicated for treating neuropathies, chronic pain, fibromyalgia, and specific neurological conditions, it has seen rampant illicit recreational abuse. The ministry flagged that youth populations are increasingly misusing the drug for its potent sedative, euphoric, and dissociative effects, backed by a spike in recent law enforcement seizures of unauthorized, black-market stockpiles.
-
Stricter Retail Record-Keeping: Under the mandatory Schedule H1 classification, pharmacies can no longer just sell the drug over the counter or via casual verification. Retailers are now legally obligated to maintain a completely separate register that records the exact details of the prescribing Registered Medical Practitioner (RMP), patient information, and the precise quantity sold. These logs must be preserved for inspection.
-
Mandatory Warning Labels: Pharmaceutical manufacturers must immediately overhaul their product packaging for Pregabalin. The boxes and strips must prominently display a distinct Schedule H1 Drug Warning layout, highlighted by a bold red text box or symbol stating: “It is dangerous to take this preparation except in accordance with medical advice.”
-
Penal Consequences for Violations: The transition significantly raises the legal stakes for compliance. Any manufacturer, stockist, wholesaler, or pharmacist found selling Pregabalin without a valid, timed RMP prescription or failing to maintain proper registers will face immediate criminal and penal action under the Drugs and Cosmetics Act, 1940.
